Related Experiment Video
Updated: May 17, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter?
1Department of Pharmacy Services, Virginia Commonwealth University Health System, Medical College of Virginia Hospitals, United States. svoils@mcvh-vcu.edu
Thrombosis Research
|November 10, 2012
Summary
Four-factor prothrombin complex concentrates (4F-PCC) more reliably normalize the international normalized ratio (INR) compared to 3-factor prothrombin complex concentrates (3F-PCC) in patients on vitamin K antagonists. This finding is crucial given the varying availability of 4F-PCC globally.
Area of Science:
- Hematology
- Pharmacology
- Clinical Medicine
Background:
- Prothrombin complex concentrates (PCCs) are vital for rapid reversal of vitamin K antagonist (VKA) effects.
- Current guidelines favor 4-factor PCCs (4F-PCC) over 3-factor PCCs (3F-PCC).
Purpose of the Study:
- To systematically compare the effectiveness of 3F-PCC versus 4F-PCC in normalizing the international normalized ratio (INR) to ≤ 1.5.
- To evaluate PCC efficacy in patients with acquired coagulopathy due to VKA use.
Main Methods:
- Systematic review of 18 studies involving 654 patients.
- Inclusion criteria: emergent VKA reversal, baseline and follow-up INR within 60 minutes of PCC administration.
Main Results:
- 4F-PCC demonstrated more consistent INR normalization to ≤ 1.5 across studies compared to 3F-PCC.
- Indications included intracerebral hemorrhage, urgent surgery, and gastrointestinal bleeding.
- Baseline INRs varied, but 4F-PCC showed superior normalization rates in follow-up.
Conclusions:
- 4F-PCC provides more reliable INR correction than 3F-PCC.
- This difference has significant clinical implications, especially where 4F-PCC availability is limited.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:19Factors Affecting Drug Biotransformation: Biological
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...